copyright 1 MG-SEMAGLUTIDE for Dummies
The trial obtained both its primary endpoints, with semaglutide two.four mg demonstrating statistically important and remarkable improvements in liver fibrosis with no worsening of steatohepatitis, and also resolution of steatohepatitis without any worsening of liver fibrosis in individuals with MASH when compared to placebo.1Excellent luck! Plan y